Update on SQNM Earnings
Posted on Monday, August 13th, 2007 | In Biotech
Contributed by: Mike Havrilla (http://mikehav.blogspot.com/) -
Sequenom Rodman & Renshaw reiterates Market Outperform. Target $7.5 to $8.5. Rodman & Renshaw raises their target on SQNM to $8.50 from $7.50, saying last night the co reported its best-ever quarterly results. Revenues handily beat estimates, and the co raised top-line guidance while maintaining its outlook on expenses. Also, firm says recent updates to the FDA’s draft guidance on diagnostic tests could bring SQNM’s non-invasive pre-natal Down syndrome test to market two years ahead of schedule.
Company also presented at investor conference last week & announced New York state approval for RhD diagnostic test is imminent.
Last 5 posts by Mike Havrilla
- Albertis $12.8B Bid to Lease PA Turnpike Expires with No Deal - October 1st, 2008
- Congress Working Overtime: $634B Spending Bill and Bailout Plan - September 27th, 2008
- Pfizer is a Big Pharma Buy - September 24th, 2008
- Bristol-Myers Ups Bid to $62 for ImClone - September 23rd, 2008
- Climate Exchange Rebounds on Robust Results - September 20th, 2008
 About Mike Havrilla (http://mikehav.blogspot.com/)
The MikeHav Market Blog provides investors with a free source of stock profiles, tools, and commentaries focused on carbon credits, the healthcare sector, exchange-traded funds (ETFs), and innovative companies across all industries.
I am a pharmacist and index developer who has been investing since August 1997 and freelance writing for investors since April 2007. I am also an avid runner since 1992 and have completed 18 marathons (26.2 miles) with a personal best time of 2 hours, 54 minutes.
I can be contacted via email at mikehavrx[at]yahoo[dot]com.
MikeHav Market Blog: www.mikehav.blogspot.com
MikeHav Market Blog RSS Feed: http://feedproxy.google.com/mikehavblog
Investment Web Domain Names [PDF]: www.geocities.com/mikehavrx/websites.pdf
Global Carbon Trading Index [PDF]: www.geocities.com/mikehavrx/ctindex.pdf |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.